15 results on '"Forman, Stephen J"'
Search Results
2. The role of allogeneic bone marrow transplantation in the treatment of high-risk acute lymphocytic leukemia in adults.
- Author
-
Forman, Stephen J.
- Subjects
- *
BONE marrow transplantation , *LYMPHOBLASTIC leukemia treatment , *DISEASE remission , *CANCER chemotherapy , *LEUKEMIA , *LEUCOCYTES , *DISEASE relapse - Abstract
Studies in the last decade show that most adults with acute lymphocytic leukemia (ALL) can achieve remission with intensive induction chemotherapy. Depending on the risk factors present at diagnosis in an individual patient, continued remissions range from less than 10% to more than 50%. The following factors have been shown to be predictive of relapse: high white cell count at diagnosis, age beyond 30, extramedullary disease at presentation, unfavorable chromosomal translocations, time longer than 6 weeks to enter remission, and use of less intensive chemotherapy for induction. Studies have been conducted to determine whether allogeneic bone marrow transplantation (BUT) could improve the outcome for patients with high-risk ALL when performed during first remission. These studies have shown that these patients have a 40% to 60% chance of disease-free survival. The current recommended strategy for patients with high-risk ALL in first remission is to undergo bone marrow transplantation prior to relapse. For those in second and subsequent remissions or those who do not achieve remission, allogeneic BUT still offers the best chance for cure of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 1997
3. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial
- Author
-
Stiff, Patrick J., Unger, Joseph M., Forman, Stephen J., McCall, Anne R., LeBlanc, Michael, Nademanee, Auayporn P., Bolwell, Brian J., and Fisher, Richard I.
- Subjects
- *
IRRADIATION , *BONE marrow transplantation , *DRUG therapy , *HODGKIN'S disease - Abstract
Several single-institution pilot studies have suggested that augmented preparative regimens, including those containing total body irradiation combined with an autologous bone marrow transplantation, are superior to standard regimens for the treatment of relapsed or refractory Hodgkin disease. On the basis of these data, we undertook, in the cooperative group setting, a phase II trial of augmented preparative regimens for patients experiencing treatment failure with conventional chemotherapy. Eighty-one patients with either sensitive or refractory (induction failures or chemoresistant) relapse received etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and either total body irradiation (12 Gy) or, if previously irradiated, carmustine (15 mg/kg), followed by an autologous bone marrow transplantation. Progression-free (PFS) and overall (OS) survival were estimated, and a Cox regression model was used to assess potential prognostic variables. The 5-year PFS and OS for the 74 eligible patients treated at 20 Southwest Oncology Group centers were 41% (95% confidence interval [CI], 29%–53%) and 54% (95% CI, 43%–65%), respectively, despite a median remission after initial chemotherapy of only 6 months. The 3-year OS for those whose induction therapy failed was 72% (95% CI, 52%–93%). There was 1 (1.4%) early treatment-related death, 2 late deaths due to lung toxicity, and only 1 death due to myelodysplasia. There were no differences in PFS or OS on the basis of regimen or chemosensitivity. A Cox prognostic factor analysis determined that >2 prior regimens, relapse in a radiated field, and extranodal disease were adverse prognostic factors. Among the 46 patients who received prior radiotherapy, the 5-year OS was 38% (95% CI, 14%–61%) for patients with 2 or 3 adverse factors, versus 60% (95% CI, 42%–78%) for those with 0 factors or 1 adverse factor. Augmented preparative regimens seem promising for the treatment of relapsed or refractory Hodgkin disease, without an increase in regimen-related mortality. A poor-prognosis group was identified that should be treated with novel therapies. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
4. Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study.
- Author
-
Arora, Mukta, Chen, Yanjun, Wu, Jessica, Hageman, Lindsey, Ness, Emily, Kung, Michelle, Francisco, Liton, Bosworth, Alysia, Weisdorf, Daniel J., Forman, Stephen J., Landier, Wendy, Pamukçuoğlu, Merve, Armenian, Saro H., Wong, F. Lennie, and Bhatia, Smita
- Subjects
- *
BONE marrow transplantation , *BONE marrow , *TRANSPLANTATION of organs, tissues, etc. , *WALKING speed , *GRAFT versus host disease - Abstract
Background: Blood or bone marrow transplantation (BMT) survivors with frailty are at a higher risk of subsequent mortality. Longitudinal trends in the frailty state are not known and could help identify vulnerable subpopulations at risk of subsequent adverse events. Methods: This study included a cohort of 470 autologous and allogeneic BMT recipients who had survived ≥2 years after BMT and completed a baseline questionnaire (t1) at a median of 7.3 years after BMT and a follow‐up questionnaire (t2) 13.2 years after t1. The main outcome was change in frailty state between t1 and t2. Frailty phenotype was defined as exhibiting ≥3 of the following characteristics: clinically underweight, exhaustion, low energy expenditure, slow walking speed, and muscle weakness. The following categories of change in frailty state were evaluated: worsened, improved, and stable. Results: Of the 470 participants, 36.4% were aged ≥60 years at t1, and 50.6% were men. The prevalence of frailty increased from 4.8% at t1 to 9.6% at t2. Worsening was observed in 18.8% of patients, and improvement was reported in 9.7%. Pre‐BMT exposure to vincristine (odds ratio [OR], 2.1; 95% CI, 1.3‐3.39) was associated with worsening. Female sex (OR, 1.5; 95% CI, 0.93‐2.4) was associated with a trend toward worsening. Pre‐BMT exposure to vincristine (OR, 2.79; 95% CI, 1.44‐5.43), a history of chronic graft‐versus‐host disease (OR, 2.58; 95% CI, 1.2‐5.5), and grade 3 and 4 chronic health conditions at t1 (OR, 2.1; 95% CI, 1.08‐4.33) were associated with frailty at t2. Conclusions: In a cohort of BMT survivors who were followed longitudinally for a median of 20.6 years from BMT, the frailty status worsened for approximately20% over a 13‐year timespan. BMT survivors who are at risk for worsening frailty could benefit from targeted interventions. In bone marrow transplantation survivors who were followed for a median of 13 years, the prevalence of frailty increased from 4.8% to 9.6%. Exposure to vincristine before bone marrow transplantation was associated with 2.1 times greater odds (95% CI, 1.3‐3.39 greater odds) of a worsening frailty state. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Haploidentical mixed chimerism cures autoimmunity in established type 1 diabetic mice.
- Author
-
Yuqing Liu, Xiaoqi Wang, Yongping Zhu, Mingfeng Zhang, Nasri, Ubaydah, Sun, Sharne S., Forman, Stephen J., Riggs, Arthur D., Xi Zhang, Defu Zeng, Liu, Yuqing, Wang, Xiaoqi, Zhu, Yongping, Zhang, Mingfeng, Zhang, Xi, and Zeng, Defu
- Subjects
- *
CHIMERISM , *AUTOIMMUNITY , *PEOPLE with diabetes , *AUTOIMMUNE diseases , *T cells , *TREATMENT of diabetes , *RESEARCH , *BONE marrow transplantation , *HOMOGRAFTS , *ANIMAL experimentation , *RESEARCH methodology , *DIABETES , *TYPE 1 diabetes , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *RESEARCH funding , *MICE - Abstract
Clinical trials are currently testing whether induction of haploidentical mixed chimerism (Haplo-MC) induces organ transplantation tolerance. Whether Haplo-MC can be used to treat established autoimmune diseases remains unknown. Here, we show that established autoimmunity in euthymic and adult-thymectomized NOD (H-2g7) mice was cured by induction of Haplo-MC under a non-myeloablative anti-thymocyte globulin-based conditioning regimen and infusion of CD4+ T cell-depleted hematopoietic graft from H-2b/g7 F1 donors that expressed autoimmune-resistant H-2b or from H-2s/g7 F1 donors that expressed autoimmune-susceptible H-2s. The cure was associated with enhanced thymic negative selection, increased thymic Treg (tTreg) production, and anergy or exhaustion of residual host-type autoreactive T cells in the periphery. The peripheral tolerance was accompanied by expansion of donor- and host-type CD62L-Helios+ tTregs as well as host-type Helios-Nrp1+ peripheral Tregs (pTregs) and PD-L1hi plasmacytoid DCs (pDCs). Depletion of donor- or host-type Tregs led to reduction of host-type PD-L1hi pDCs and recurrence of autoimmunity, whereas PD-L1 deficiency in host-type DCs led to reduction of host-type pDCs and Helios-Nrp1+ pTregs. Thus, induction of Haplo-MC reestablished both central and peripheral tolerance through mechanisms that depend on allo-MHC+ donor-type DCs, PD-L1hi host-type DCs, and the generation and persistence of donor- and host-type tTregs and pTregs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study.
- Author
-
Arora, Mukta, Chen, Yanjun, Hageman, Lindsey, Wu, Jessica, Landier, Wendy, Francisco, Liton, Kung, Michelle, Ness, Emily, Bosworth, Alysia, Pamukcuoglu, Merve, Weisdorf, Daniel J., Forman, Stephen J., Armenian, Saro H., and Bhatia, Smita
- Subjects
- *
BONE marrow transplantation , *AUTOTRANSPLANTATION , *MULTIPLE myeloma , *DISEASES , *HEMATOPOIETIC stem cell transplantation , *MELANOMA ,BONE marrow examination - Abstract
Background: Autologous blood or bone marrow transplantation (aBMT) is considered the standard of care for patients with multiple myeloma (MM). Significantly improved survival necessitates an understanding of the morbidity burden borne by the growing survivor population.Methods: The authors evaluated severe and/or life-threatening chronic health conditions (CHCs) and subsequent neoplasms (SNs) in patients with MM who were treated with aBMT using the Bone Marrow Transplant Survivor Study. A total of 630 study participants had undergone aBMT for MM at 1 of 3 BMT centers, had survived ≥2 years after aBMT, and were aged ≥18 years at the time of survey completion. Survivors of aBMT identified 289 nearest-age siblings to constitute an unaffected comparison group. Scoring of CHCs was based on version 5 of the National Cancer Institute Common Terminology Criteria for Adverse Events to determine severity (with grade 3 indicating serious and grade 4 indicating life-threatening).Results: The 10-year cumulative incidence of any grade 3 to 4 CHC among survivors of aBMT was 57.6 ± 3.2%. Survivors of MM were found to be at 40% higher odds of developing grade 3 to 4 CHCs when compared with siblings (95% confidence interval [95% CI], 1.0-1.9). Among SNs, 96% were solid tumors, yielding a 10-year cumulative incidence of 13.6% ± 2.5%. Pre-aBMT exposure to cyclophosphamide (hazard ratio [HR], 3.5; 95% CI, 1.5-8.1) and immunomodulatory drugs (HR, 3.9; 95% CI, 1.5-10.1) were associated with an increased risk of solid tumors. Melanoma (10-year cumulative incidence: 3.3% ± 1.2%) and squamous cell carcinoma (10-year cumulative incidence: 5.1% ± 1.8%), were the most common SNs. Pre-aBMT exposure to cyclophosphamide (HR, 6.02; 95% CI, 1.4-26.1) and immunomodulatory drugs (HR, 7.9; 95% CI, 0.9-68.5) was associated with an increased risk of melanoma.Conclusions: The 10-year cumulative incidence of severe and/or life-threatening CHCs was found to approach 60% in long-term survivors of MM, with solid SNs constituting a large morbidity burden. The current study has provided evidence supporting the close monitoring of survivors to manage morbidity. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. Self-endorsed cognitive problems versus objectively assessed cognitive impairment in blood or bone marrow transplantation recipients: A longitudinal study.
- Author
-
Murdaugh, Donna L., Bosworth, Alysia, Patel, Sunita K., Sharafeldin, Noha, Chen, Yanjun, Francisco, Liton, Forman, Stephen J., Wong, F. Lennie, and Bhatia, Smita
- Subjects
- *
COGNITION disorders , *BONE marrow transplantation , *COGNITIVE testing , *LONGITUDINAL method , *BLOOD , *RESEARCH , *SELF-evaluation , *BLOOD transfusion , *RESEARCH methodology , *BLOOD transfusion reaction , *CASE-control method , *EVALUATION research , *MEDICAL cooperation , *NEUROPSYCHOLOGICAL tests , *COMPARATIVE studies , *RESEARCH funding - Abstract
Background: Cognitive impairment in survivors of blood or bone marrow transplantation (BMT) is well documented. However, to the authors' knowledge, the clinical relevance of self-endorsed cognitive problems and their relation to objectively assessed cognitive impairment is not known.Methods: The authors assessed cognitive impairment in 378 BMT recipients (median age, 52.2 years, 40% of whom were female and 68% of whom were non-Hispanic white) and 98 healthy controls at 5 predetermined time points: at baseline (before BMT) and at 6 months, 1 year, 2 years, and 3 years after BMT. Self-endorsed cognitive problems were evaluated using the Neuropsychological Impairment Scale (NIS) and correlated with a standardized 2-hour battery of objective cognitive testing at each time point. The authors examined the magnitude of difference in self-endorsed cognitive problems between BMT recipients and healthy controls, and the rate of change in scores over time. Multivariable analyses were used to identify clinical and/or demographic variables associated with self-endorsed cognitive problems. The authors also examined the association between cognitive impairment and returning to work after BMT.Results: Compared with healthy controls, BMT recipients endorsed more cognitive problems (P < .001) at all time points, and the rate of change in NIS scores was found to be significantly greater in BMT recipients. Fatigue was associated with greater endorsement of cognitive problems at 1 year after BMT (odds ratio, 4.23; 95% CI, 2.1-8.3 [P < .001]). Overall, there was a statistically significant, modest correlation noted between self-endorsed cognitive problems and objective cognitive impairment (range, 0.401-0.445 [P ≤ .01]). Higher self-endorsed cognitive problems were associated with a 3.7-fold (P = .02) higher odds of not returning to work at 3 years after BMT.Conclusions: The results of the current study demonstrated that self-endorsed cognitive problems can help to identify vulnerable patient subpopulations for detailed cognitive assessment and possible cognitive remediation. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation.
- Author
-
Gangaraju, Radhika, Chen, Yanjun, Hageman, Lindsey, Wu, Jessica, Francisco, Liton, Kung, Michelle, Ness, Emily, Parman, Mariel, Weisdorf, Daniel J., Forman, Stephen J., Arora, Mukta, Armenian, Saro H., and Bhatia, Smita
- Subjects
- *
BONE marrow , *THROMBOEMBOLISM , *BODY mass index , *TRANSPLANTATION of organs, tissues, etc. , *GRAFT versus host disease , *VENOUS insufficiency , *LYMPHOMA treatment , *BLOOD transfusion , *BONE marrow transplantation , *COMPARATIVE studies , *LONGITUDINAL method , *LYMPHOMAS , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RISK assessment , *VEINS , *EVALUATION research , *DISEASE incidence , *DISEASE complications ,BONE marrow examination ,THROMBOEMBOLISM prevention - Abstract
Background: Patients with non-Hodgkin lymphoma (NHL) have an increased risk of venous thromboembolism (VTE), particularly when they are receiving treatment. Blood or marrow transplantation (BMT) is recommended for relapsed/refractory NHL, and the risk of VTE after these patients undergo BMT is uncertain.Methods: Patients with NHL who survived 2 years or longer after BMT were surveyed for long-term health outcomes, including VTE. The median follow-up was 8.1 years (interquartile range, 5.6-12.9 years). The risk of VTE in 734 patients with NHL versus 897 siblings without a history of cancer and the risk factors associated with VTE were analyzed.Results: BMT survivors of NHL were at increased risk for VTE in comparison with siblings (odds ratio for allogeneic BMT survivors, 4.61; P < .0001; odds ratio for autologous BMT survivors, 1.75; P = .035). The cumulative incidence of VTE was 6.3% ± 0.9% at 5 years after BMT and 8.1% ± 1.1% at 10 years after BMT. In allogeneic BMT recipients, an increased body mass index (BMI; hazard ratio [HR] for BMI of 25-30 kg/m2 , 3.52; 95% confidence interval [CI], 1.43-8.64; P = .006; HR for BMI > 30 kg/m2 , 3.44; 95% CI, 1.15-10.23; P = .027) and a history of chronic graft-versus-host disease (HR, 3.33; 95% CI, 1.59-6.97; P = .001) were associated with an increased risk of VTE. Among autologous BMT recipients, a diagnosis of coronary artery disease (HR, 5.94; 95% CI, 1.7-20.71; P = .005) and prior treatment with carmustine (HR, 4.91; 95% CI, 1.66-14.51; P = .004) were associated with increased VTE risk.Conclusions: Patients with NHL who survive BMT are at risk for developing late occurring VTE, and ongoing vigilance for this complication is required. Future studies assessing the role of thromboprophylaxis in high-risk patients with NHL are needed. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report.
- Author
-
Holmqvist, Anna Sällfors, Yanjun Chen, Wu, Jessica, Battles, Kevin, Bhatia, Ravi, Francisco, Liton, Hageman, Lindsey, Kung, Michelle, Ness, Emily, Parman, Mariel, Salzman, Donna, Winther, Jeanette Falck, Rosenthal, Joseph, Forman, Stephen J., Weisdorf, Daniel J., Arora, Mukta, Armenian, Saro H., and Bhatia, Smita
- Subjects
- *
BONE marrow transplantation , *CHILDHOOD cancer , *CANCER relapse , *CANCER patients , *MORTALITY - Abstract
Autologous blood or marrow transplantation (BMT) is a curative option for several types of childhood cancer. However, there is little information regarding the risk of late mortality. We examined all-cause mortality, relapse-related mortality (RRM), and nonrelapse-related mortality (NRM) in 2-year survivors of autologous BMT performed before age 22 between 1980 and 2010 at 1 of 2 US transplant centers. Vital status information was collected using medical records, National Death Index, and Accurint databases. Overall survival was calculated using Kaplan-Meier techniques. Cumulative incidence of mortality used competing risk methods. Standardized mortality ratio (SMR) was calculated using age-, sex-, and calendar-specific mortality rates from Centers for Disease Control and Prevention. Cox regression analysis was used to determine predictors of all-cause late mortality. Among the 345 2-year survivors, 103 deaths were observed, yielding an overall survival of 70.3% 15 years post-BMT. The leading causes of death included primary disease (50.0%), subsequent neoplasm (21.4%), and infection (18.2%). Overall, the cohort was at a 22-fold increased risk of late mortality (SMR, 21.8; 95% Cl, 17.9-26.3), compared with the general population. Mortality rates remained elevated among the 10-year survivors (SMR, 20.6; 95% Cl, 9.9-37.2) but approached those of the general population £15 years post-BMT. The 10-year cumulative incidence of RRM (14.3%) exceeded that of NRM (10.4%). The 10-year cumulative mortality rate declined over time (<1990, 35.1%; 1990-1999, 25.6%; 2000-2010, 21.8%; P = .05). In conclusion, childhood autologous BMT recipients have an increased risk of late mortality, compared with the general population. The late mortality rates have declined over the past 3 decades. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.
- Author
-
Alvarnas, Joseph C., Le Rademacher, Jennifer, Yanli Wang, Little, Richard F., Akpek, Gorgun, Ayala, Ernesto, Devine, Steven, Baiocchi, Robert, Lozanski, Gerard, Kaplan, Lawrence, Noy, Ariela, Popat, Uday, Hsu, Jack, Morris Jr., Lawrence E., Thompson, Jason, Horowitz, Mary M., Mendizabal, Adam, Levine, Alexandra, Krishnan, Amrita, and Forman, Stephen J.
- Subjects
- *
CELL transplantation , *AIDS-related lymphoma , *BONE marrow transplantation , *CARMUSTINE , *CYTARABINE , *AIDS treatment , *THERAPEUTICS - Abstract
Autologous hematopoietic cell transplant (AHCT) for HIV-infected patients is largely limited to centers with HIV-specific expertise. The Blood and Marrow Transplant Clinical Trials Network 0803/AIDS Malignancy Consortium 071 trial is a multicenter phase 2 study of AHCT for patients with HIV-related lymphoma (HRL). Eligible patients had chemotherapy-sensitive relapsed/persistent HRL, were >15 years of age, and had treatable HIV infection. Patients were prepared using carmustine, etoposide, cytarabine, and melphalan and received consistent management of peritransplant antiretroviral treatment. The primary endpoint was 1-year overall survival. Forty-three patients were enrolled; 40 underwent AHCT. Pretransplant HIV viral load was undetectable (<50 copies/mL) in 32 patients (80%); the median CD4 count was 249/mL (range, 39-797). At a median follow-up of 24.8 months, 1-year and 2-year overall survival probabilities were 87.3% (95% confidence interval [CI], 72.1-94.5) and82%(95% CI, 65.9-91), respectively. The probability of 2-year progression-free survival was 79.8% (95% CI, 63.7-89.4). One-year transplant-related mortality was 5.2%. Median time to neutrophil and platelet recovery was 11 days and 18 days, respectively. Nine patients experienced a total of 13 unexpected grade 3-5 adverse events posttransplant (10 grade 3 and 3 grade 4 events). Twenty-two patients had at least 1 infectious episode posttransplant. At 1 year post-AHCT, medianCD41 T-cell count was 280.3 (range, 28.8-1148.0); 82.6% had an undetectable HIV viral load. Trial patients were compared with 151 matched Center for International Bone Marrow Transplant Research controls. Outcomes between HIV-infected patients and controls were not statistically significantly different. HRL patients should be considered candidates for AHCT if they meet standard transplant criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Burden of Morbidity in 10+ Year Survivors of Hematopoietic Cell Transplantation: Report from the Bone Marrow Transplantation Survivor Study.
- Author
-
Sun, Can-Lan, Kersey, John H., Francisco, Liton, Armenian, Saro H., Baker, K. Scott, Weisdorf, Daniel J., Forman, Stephen J., and Bhatia, Smita
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *CANCER-related mortality , *MEDICAL care , *COMPARATIVE studies , *BONE marrow transplantation , *ADVERSE health care events , *PSYCHOPHYSIOLOGY - Abstract
Abstract: Long-term morbidity after hematopoietic cell transplantation (HCT) is unknown. The risk of physical and psychological health in 324 patients who had survived 10 or more years after HCT and a sibling comparison group (n = 309) was evaluated. Using the Common Terminology Criteria for Adverse Events, the 15-year cumulative incidence of severe/life-threatening/fatal conditions was 41% (95% confidence interval, 34% to 48%). HCT survivors were 5.7 times as likely to develop a severe/life-threatening condition (P < .001) and 2.7 times as likely to report somatic distress (P < .001) compared with siblings. Compared with allogeneic HCT recipients with no chronic graft-versus-host disease (GVHD), those with active chronic GVHD were at a 1.8-fold higher risk of severe/life-threatening health conditions (P = .006) and a 4.5-fold higher risk of somatic distress (P = .04); allogeneic HCT recipients with resolved chronic GVHD were not at increased risk of morbidity compared with those with no chronic GVHD. Only 27% of the HCT survivors returned to the transplantation center for their cancer-related care. The burden of long-term physical and emotional morbidity borne by survivors remains substantial, even beyond 10 years after HCT; however, specialized health care is underused. Patients, families, and healthcare providers need to be made aware of the high burden, so they can plan for post-HCT care, even many years after HCT. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
12. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow.
- Author
-
Mielcarek, Marco, Storer, Barry, Martin, Paul J., Forman, Stephen J., Negrin, Robert S., Flowers, Mary E., Inamoto, Yoshihiro, Chauncey, Thomas R., Storb, Rainer, Appelbaum, Frederick R., and Bensinger, William I.
- Subjects
- *
TRANSPLANTATION immunology , *COMPARATIVE studies , *HEALTH outcome assessment , *HLA histocompatibility antigens , *BONE marrow transplantation , *MEDICAL statistics - Abstract
Between 1996 and 1999,172 patients (median age, 42 years) with hematologic malignancies were randomly assigned to receive either HLA-identical related bone marrow or G-CSF-mobilized peripheral blood mononuclear cells (G-PBMCs) after myeloablative conditioning. Early results showed that transplantation of G-PBMCs, compared with marrow, was associated with significantly superior 2-year disease free survival (DFS) and overall survival. Ten-year follow-up showed a sustained DFS benefit associated with G-PBMCs (mortality or relapse hazard ratio, 0.64; 95% confidence interval, 0.4-1.0; P = .03), although the likelihood of overall survival was not significantly different between the 2 groups (mortality hazard ratio, 0.75; 95% confidence interval, 0.5-1.2; P = .20). The 10-year cumulative incidence of chronic GVHD and the duration of systemic immunosuppression were similar in the 2 groups. In summary, transplantation of HLA-identical related G-PBMCs, compared with marrow, was associated with superior short-term and long-term DFS, and there was no evidence that this benefit was outweighed by GVHD-related late mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
13. Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS).
- Author
-
Can-Lan Sun, Francisco, Liton, Baker, K. Scott, Weisdorf, Daniel J., Forman, Stephen J., and Bhatia, Smita
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HEMATOPOIETIC system , *BONE marrow transplantation , *IMMUNE system , *TRANSPLANTATION of organs, tissues, etc. , *CELL transplantation , *PSYCHOLOGY - Abstract
Little information exists regarding long-term psychological health of hematopoietic cell transplantation (HCT) survivors. Using resources offered by the Bone Marrow Transplant Survivor Study (BMTSS), we evaluated adverse psychological outcomes in 1065 long-term HCT survivors and a healthy comparison group composed of siblings. Psychological health status was evaluated using the Brief Symptom Inventory-18. Twenty-two percent of the HCT survivors reported adverse psychological outcomes, compared with 8% of the siblings. Exposure to prednisone was associated with psychological distress across all domains (anxiety, depression, and somatic distress). Fifteen percent of the HCT survivors reported somatic distress, representing an almost 3-fold higher risk comparing to siblings. Among survivors, in addition to low annual household income and self-reported poor health, having severe/life-threatening conditions and presence of active chronic GVHD were associated with a 2-fold increased risk for somatic distress. Seven percent of the HCT survivors expressed suicidal ideation; patients with higher scores on depression subscale were most vulnerable. This study demonstrates that somatic distress is the biggest challenge faced by survivors long after HCT. These results identify vulnerable subpopulations and provide patients, families, and healthcare providers with necessary information to plan for post-HCT needs many years after HCT. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
14. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).
- Author
-
Armenian, Saro H., Can-Lan Sun, Kawashima, Toana, Arora, Mukta, Leisenring, Wendy, Sklar, Charles A., Baker, K. Scott, Francisco, Liton, Berano The, Jennifer, Mills, George, Wong, F. Lennie, Rosenthal, Joseph, Diller, Lisa R., Hudson, Melissa M., Oeffinger, Kevin C., Forman, Stephen J., Robison, Leslie L., and Bhatia, Smita
- Subjects
- *
CHILDHOOD cancer , *HEMATOLOGY , *BONE marrow transplantation , *SIBLINGS , *CHRONIC diseases - Abstract
HSCT is being increasingly offered as a curative option for children with hematologic malignancies. Although survival has improved, the long-term morbidity ascribed to the HSCT procedure is not known. We compared the risk of chronic health conditions and adverse health among children with cancer treated with HSCT with survivors treated conventionally, as well as with sibling controls. HSCT survivors were drawn from BMTSS (N = 145), whereas conventionally treated survivors (N = 7207) and siblings (N = 4020) were drawn from CCSS. Self- reported chronic conditions were graded with CTCAEv3.0. Fifty-nine percent of HSCT survivors reported ≥ 2 conditions, and 25.5% reported severe/life-threatening conditions. HSCT survivors were more likely than sibling controls to have severe/life-threatening (relative risk [RR] = 8.1, P < .01)and 2 or more(RR = 5.7, p < .01) conditions, as well as functional impairment (RH = 7.7, p < .01) and activity limitation (RR = 6.3, p < .01). More importantly, compared with CCSS survivors, BMTSS survivors demonstrated significantly elevated risks (severe/life-threatening conditions: RR = 3.9, p < .01; multiple conditions: RR = 2.6, p < .01; functional impairment: RR = 3.5, p < .01; activity limitation: AR = 5.8, p < .01). Unrelated donor HSCT recipients were at greatest risk. Childhood HSCT survivors carry a significantly greater burden of morbidity not only compared with noncancer populations but also compared with conventionally treated cancer patients, providing evidence for close monitoring of this high-risk population. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Older Survivors of Allogeneic Hematopoietic Cell Transplantation (HCT) with Chronic Graft Vs. Host Disease (cGvHD) Demonstrate Higher Risk of Frailty As Compared with Autologous HCT Recipients: A Report from the Bone Marrow Transplant Survivor Study-2.
- Author
-
Arora, Mukta, Sun, Canlan, Ness, Kirsten, Teh, Jennifer Berano, Schad, Amy, Hanby, Cara, Francisco, Liton, Hou, Karen, Wu, Jessica, Kuo, Linus, Armenian, Saro H., Weisdorf, Daniel J., Forman, Stephen J., and Bhatia, Smita
- Subjects
- *
GRAFT versus host disease , *DISEASES in older people , *HEMATOPOIETIC stem cell transplantation , *FRAGILITY (Psychology) , *AUTOGRAFTS , *BONE marrow transplantation , *THERAPEUTICS - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.